MANAGEMENT AND COST OF SCIATICA IN-HOSPITAL
Author(s)
Dinet J1, Poullie AI1, Malafaye N2, Aubas P2, Dujols P2, Cyteval C31Innovations & Health Economics Unit, University Hospital of Montpellier, Montpellier, France, 2Medical Information Unit, University Hospital of Montpellier, Montpellier, France, 3Radiology Dept, University Hospital of Montpellier, Montpellier, France
OBJECTIVES: To describe the disease management and the cost of patients presenting a diagnosis of sciatica in the hospital perspective. METHODS: We performed a local data base request from the medical information system (PMSI) of the University Hospital of Montpellier. We considered three consecutive years (2006, 2007, 2008) which allowed us to get a follow-up and a traceability of patients over this period. We analyzed a group of patients 18-50 years old admitted across acute care, day care or mid-term care sectors with the following diagnosis codes M 54, M 5415, M 5416 and M 5417 of the ICD-10. RESULTS: A total of 232 patients were selected over the period representing a total of 541 admissions (i.e. 2.3 admissions per patient). The mean ± SD age was 39 ± 8 years female represent 45% of the patients. We observed 175 admissions in acute care ("less than 24 h" admissions excluded) with a mean length of stay of 7 ± 5.2 days. Day-care represents 15.4% of admission in acute care sector. We observed 38 admissions in mid-term care with a mean length of stay of 3 ± 4.8 days. Few patients (3 %) were admitted consecutively in acute care and in mid term care thereafter. Surgery was the reason of first admission for six patients. The cost is estimated at €2055 per patient admitted in an acute care sector. CONCLUSIONS: In our sample, we noted a high rate of admission per patient for diagnosis, medical treatment or physical therapy reasons as the main pattern of sciatica management in-hospital. Admissions for surgery were marginal. Our figures are key information to specify management of sciatica and transition probabilities in decision tree models. Thus, we would simulate the impact of innovative medical device on the burden of disease and disclose where are the most prominent societal benefits.
Conference/Value in Health Info
2009-10, ISPOR Europe 2009, Paris, France
Value in Health, Vol. 12, No. 7 (October 2009)
Code
PMS18
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis, Cost/Cost of Illness/Resource Use Studies
Disease
Musculoskeletal Disorders